- Open Access
Cost-effectiveness of smoking cessation to prevent age-related macular degeneration
© Hurley et al; licensee BioMed Central Ltd. 2008
- Received: 14 January 2008
- Accepted: 11 September 2008
- Published: 11 September 2008
Tobacco smoking is a risk factor for age-related macular degeneration, but studies of ex-smokers suggest quitting can reduce the risk.
We fitted a function predicting the decline in risk of macular degeneration after quitting to data from 7 studies involving 1,488 patients. We assessed the cost-effectiveness of smoking cessation in terms of its impact on macular degeneration-related outcomes for 1,000 randomly selected U.S. smokers. We used a computer simulation model to predict the incidence of macular degeneration and blindness, the number of quality-adjusted life-years (QALYs), and direct costs (in 2004 U.S. dollars) until age 85 years. Cost-effectiveness ratios were based on the cost of the Massachusetts Tobacco Control Program. Costs and QALYs were discounted at 3% per year.
If 1,000 smokers quit, our model predicted 48 fewer cases of macular degeneration, 12 fewer cases of blindness, and a gain of 1,600 QALYs. Macular degeneration-related costs would decrease by $2.5 million if the costs of caregivers for people with vision loss were included, or by $1.1 million if caregiver costs were excluded. At a cost of $1,400 per quitter, smoking cessation was cost-saving when caregiver costs were included, and cost about $200 per QALY gained when caregiver costs were excluded. Sensitivity analyses had a negligible impact. The cost per quitter would have to exceed $77,000 for the cost per QALY for smoking cessation to reach $50,000, a threshold above which interventions are sometimes viewed as not cost-effective.
Smoking cessation is unequivocally cost-effective in terms of its impact on age-related macular degeneration outcomes alone.
- Chronic Obstructive Pulmonary Disease
- Smoking Cessation
- Macular Degeneration
- Geographic Atrophy
There is a strong association between tobacco smoking and age-related macular degeneration. A pooled analysis of data from the 3 largest population-based prevalence surveys found risks for current smokers relative to never smokers were 4.55-fold higher for neovascular age-related macular degeneration and 2.54-fold higher for geographic atrophy. These relative risks were approximately halved in ex-smokers, suggesting that the adverse effect of smoking is reversible.[1, 2] Despite these findings, the management of macular degeneration has focused on treatment rather than prevention.
Previous analyses of the economics of smoking cessation have considered the improved quality of life, increased life expectancy and lower health care expenditures associated with the reduced incidence of illnesses such as cardiovascular disease, stroke, lung cancer and chronic obstructive pulmonary disease. [3–5] These analyses have found that interventions that encourage and facilitate quitting are very cost-effective, with net cost savings in some instances. However the economic impact of quitting on macular degeneration has not been analysed.
The purpose of the present analysis was therefore to quantify the health and health economic benefits of smoking cessation in relation to age-related macular degeneration alone. We estimated the cost-effectiveness of a tobacco control program in terms of prevention of blindness and improvement in quality of life as a consequence of the decreased risk of macular degeneration. We based our estimates of the cost of quitting on the Massachusetts Tobacco Control program conducted in the 1990s, and which had the highest per capita expenditure on tobacco control in the world. Our analyses investigated the extent to which the cost of such smoking cessation programs will be offset by savings in the cost of care and medical treatment due to prevention of vision loss.
We developed a Markov model to simulate the risk and progression of macular degeneration in cigarette smokers and quitters in the United States, my modifying a Markov model we had published previously. The previous model was designed to assess the cost-effectiveness of ranibizumab, a new treatment for the neovascular form of macular degeneration. Both it, and the model reported here, were programmed using the decision analysis software TreeAge. The smoking and macular degeneration model predicted the following outcomes for smokers and quitters: the probability of developing macular degeneration, the probability of blindness (defined as visual acuity < 35 letters read on the logMAR chart, or Snellen equivalent < 20/200), the number of years spent blind (blind-years), the number of quality-adjusted life-years (QALYs), and direct costs (excluding patient time and travel costs) from a societal perspective in 2004 U.S. dollars.
The Markov model tracked subjects in each 5-year age group from 15–19 years for the remainder of their lifetime, censored at age 85 years. Each year, subjects were at risk of developing either the neovascular or the geographic atrophy form of macular degeneration, or dying. The neovascular form (or "wet" age-related macular degeneration) involves serous or haemorrhagic detachment of the retinal pigment epithelium or sub-retinal pigment epithelial haemorrhages. Geographic atrophy (or "dry" age-related macular degeneration) involves a discrete area of retinal depigmentation with a sharp border and visible choroidal vessels. Disease progression for subjects who developed macular degeneration was characterized by a series of annual transitions between health states, defined by visual acuity, as described in our previous paper. Briefly, the five health states considered corresponded to the number of letters read on the log-MAR chart being > 85, 70–80, 55–65, 40–50, and < 35 (blind). We assumed that, each year, a patient's visual acuity would increase by 15 letters, remain the same, decrease by 15 letters, or decrease by 30 letters. We assumed that smoking cessation decreased the risk of developing macular degeneration and the risk of death from all causes, but did not affect disease progression. For each 5-year age-group, for males and females separately, the course of 10,000 smokers was simulated one at a time, firstly assuming that each subject continued to smoke, then assuming that all subjects quit.
We assessed the macular degeneration-related benefits of smoking cessation by comparing outcomes for a hypothetical cohort of 1,000 smokers. This cohort was randomly selected, stratified by 5-year age-group and sex, from a population simulated to represent the U.S. population of smokers in 2004. Cost-effectiveness ratios were estimated using data on the cost of smoking cessation from the comprehensive Massachusetts Tobacco Control Program, conducted in the 1990s. Future costs, blind-years and QALYs were discounted at 3% per year.
Estimates for model variables
Incidence of age-related macular degeneration in smokers
Annual incidence probabilities of age-related macular degeneration for current smokers and ex-smokers who quit 15 years previously*
Type of age-related macular degeneration and age range
Smoker (per 1000)†
Quitter (per 1000)‡
< 55 years
< 55 years
Incidence of age-related macular degeneration in quitters
Through a comprehensive MEDLINE search combining the search terms "smoking" and "macular degeneration", we identified 7 studies that reported the risk of age-related macular degeneration for ex-smokers by time since quitting: 2 prospective cohort studies,[14, 15] 2 case-control studies[16, 17], and 3 cross-sectional studies. [18–20] These studies analysed the smoking profiles of a total of 1,488 people with age-related macular degeneration. We extracted data on the relative risk of age-related macular degeneration for ex-smokers relative to never-smokers and the time after quitting that each risk was assessed. In the study by Seddon et al. risks were reported relative to current-smokers, and we therefore divided them by the risks for never-smokers relative to current-smokers to obtain risks for ex-smokers relative to never smokers. Where time was reported in the publication as a range, we took the time since quitting to be the midpoint; for example, < 20 years and 5 – 14 years were recorded as 10 years. Where time was reported as "greater than" or "equal or greater than" a specified number of years, we took the time since quitting to be the specified time plus 10 years, so > 20 years and ≥ 20 years were recorded as 30 years.
We assumed the following model for the risk, RR(t), of age-related macular degeneration for ex-smokers relative to never-smokers: RR(t) = [(RR0- 1)]e-t/τ + 1
RR0 was the relative risk of developing age-related macular degeneration for current-smokers versus never-smokers
t was the time, in months, since quitting
τ was a slope parameter that was inversely proportional to the rate at which the relative risk decreased with time since quitting.
We assumed that the asymptotic value of the relative risk, RR(∞), was 1, i.e., that the risk of developing macular degeneration for quitters eventually equalled the risk for never-smokers. The data from the 7 studies were consistent with this assumption. Six of the 7 studies had a RR measured or inferred at 30 years, and values ranged from 0.85 to 1.5. We assumed that RR0 depended on the particular study population and the type of macular degeneration (neovascular or geographic atrophy). A separate value for RR0 was therefore estimated for each study. However, due to the paucity of data, we assumed that the parameter τ did not depend on age, or sex, or the type of macular degeneration.
The values of RR0 and τ were estimated by fitting the non-linear model: ln(RR(t)) = ln([(RR0- 1)]e-t/τ + 1) + ε
where the regression errors (ε) were assumed to be independent.
The analyses were carried out using the non-linear regression procedure (Levenberg-Marquardt estimation method) in the SPSS software package. The natural logarithms of the relative risks were weighted proportional to the inverse of their variances, which were estimated from the reported confidence intervals for the relative risks. As confidence intervals were unavailable for the relative risks calculated from the data reported by Seddon and colleagues, the variances of the natural logarithms of the relative risks were conservatively estimated by summing the variances of the natural logarithms of the risks of ex-smokers relative to current-smokers and those of never-smokers relative to current-smokers.
In our Markov model of the impact of smoking cessation on age-related macular degeneration, we needed estimates of the risks, for ex-smokers relative to current-smokers, over time since quitting.
We therefore used the model parameter estimate that describes the rate of decline in the relative risk, and the risks of each type of macular degeneration for smokers relative to never-smokers to calculate the risk, each year after quitting, of neovascular macular degeneration and geographic atrophy, for an ex-smoker relative to a current smoker, using the following formulae.
By definition: rr(t) = RR(t)/RR0
or rr(t) = [(1-1/RR0)]e-t/τ + 1/RR0.
The values of RR0 (the risks of macular degeneration for current smokers relative to never smokers) for neovascular disease and geographic atrophy were assumed to be 4.55 (asymptotic 95% CI: 2.74 – 7.54) and 2.54 (asymptotic 95% CI: 1.25 – 5.17), respectively.
Therefore, for neovascular age-related macular degeneration: rr(t) = 0.220 e-t/165 + 0.780
and, for geographic atrophy: rr(t) = 0.606 e-t/165 + 0.394
Progression, treatment and costs of age-related macular degeneration
Our assumptions about the distribution of visual acuity at diagnosis of age-related macular degeneration, disease progression, treatment and costs came from a previous paper in which we analysed the cost-effectiveness of ranibizumab, a new treatment for the neovascular form of macular degeneration.
We assumed that 90% of patients with the neovascular form of disease were treated with ranibizumab, that ranibizumab's cost was the current wholesale price ($1,950 per dose)and that its effectiveness and dosing regimen corresponded to the base-case scenario described in the previous paper, i.e. it was effective for 4 years, during which time it was given monthly for the first 2 years then 3 monthly. Costs for geographic atrophy-related medical care (which were not considered in the ranibizumab cost-effectiveness analysis) were sourced from Halpern and colleagues' analyses of Medicare files. We converted the average annual cost for patients with "dry only" disease ($345 in 2001 dollars) to 2004 U.S. dollars ($395) using the medical care Consumer Price Index.
We assumed vision loss was associated with reduced quality of life, and used the visual acuity-specific utility estimates from patients with age-related macular degeneration sourced for the ranibizumab cost-effectiveness analysis.[7, 25] We assumed there was no reduction in utility associated with smoking or quitting.
Probabilities of death for smokers and quitters
We used the method previously described,  and referred to above for the incidence of macular degeneration in smokers, to estimate probabilities of death for smokers from all causes mortality data for the general U.S. population in 2004. Smoking prevalence in 2004–5 and relative risks of all causes mortality for smokers from the American Cancer Society (ACS) Cancer Prevention Study (CPS-II) the U.S. were used in the calculations.
Quitters' mortality probabilities were estimated by applying a function that described the decline in the risk of death from all causes for quitters relative to smokers to the probability of death for smokers. The function was based on data from the ACS CPS-II. 
Cost per quitter
The Massachusetts tobacco control program started in 1993, and spent over $200 million by 1999 on interventions including a mass media campaign, services such as treatment and telephone counselling to help smokers quit, and promotion of local policies. By 1999, the adult smoking prevalence in Massachusetts was 3.9% lower than in 48 other U.S. states without such programs.[6, 28] This represented about 183,600 fewer adult smokers, based on the number of people aged 18 and over in Massachusetts in 1999. The cost per quitter was therefore assumed to be $1,400 after adjusting the cost of the program (assumed to be in 1995 U.S. dollars) to 2004 dollars on the basis of the Consumer Price Index.
We performed sensitivity analyses to investigate the impact of key model assumptions on QALYs, costs and the incremental cost per QALY gained. The parameter that describes the rate of decline in risk of macular degeneration after quitting was varied from its low to its high 95% confidence limit, and different assumptions about the disutility of vision loss and treatment of neovascular age-related macular degeneration were investigated. A threshold analysis was conducted to determine the cost per quitter that gave a cost per QALY for smoking cessation of $50,000.
Expected Lifetime* AMD-related† Health Outcomes for 1,000 Randomly Selected Smokers,‡ who either Continue Smoking or Quit.
AMD-related Health Outcomes
Benefits of quitting
Cases of AMD
Cases of blindness§
Expected Lifetime* AMD-related† Costs for 1,000 Randomly Selected Smokers‡ who either Continue Smoking or Quit, and Cost-Effectiveness Ratios for a Tobacco Control program.§.
Lifetime AMD-related costs
Cost-effectiveness Ratios (assuming a cost per quitter of $1,400)
Benefit of quitting
Cost per case of blindness prevented
Cost per blind-year prevented
Cost per QALY gained
Including caregiver costs
Excluding caregiver costs
Sensitivity Analyses of the Lifetime* AMD-related† Benefits of Quitting for 1,000 Randomly Selected Smokers‡, and Cost-Effectiveness of a Tobacco Control Program.§.
Lifetime AMD-related Benefits of Quitting
Cost per QALY gained (assuming a cost per quitter of $1,400)
Costs (excluding caregivers) $
Slope parameter (τ), which is inversely proportional to the rate of decline in the risk of AMD after quitting relative to current-smokers
Upper 95% confidence Limit (slower decline)
Lower 95% confidence Limit (faster decline)
Higher utilities for reduced visual acuity ¶
Ranibizumab treatment of neovascular AMD ||
Base-case scenario, as in Table 3, but:
low ranibizumab cost
50% of neovascular patients treated
Sustained-effect scenario, low ranibizumab cost
Non-sustained effect scenario, high ranibizumab cost
The 2004 U.S. Surgeon General's report concluded that the available evidence was suggestive of a causal relationship between smoking and both neovascular and atrophic age-related macular degeneration, and summarized 3 biologic mechanisms whereby smoking might exacerbate or accelerate the degenerative changes that occur in the macula with age. A subsequent review, that included 5 additional studies, confirmed a strong association between current smoking and age-related macular degeneration which fulfilled accepted causality criteria, and concluded that there was evidence of reversibility. We quantified the reduction in risk over time since quitting smoking, using data from 7 studies involving 1,488 people with age-related macular degeneration. [14–20] Although none of the studies monitored the incidence of macular degeneration prospectively in ex-smokers from the time of quitting, all studies found a reduced risk 10 years or more after ex-smokers reported having quit.
We assessed the benefits of smoking cessation in terms of the reduced incidence, morbidity and direct costs of age-related macular degeneration experienced by ex-smokers compared with smokers. In order to concentrate attention on macular degeneration, the numerous other benefits associated with quitting, such as morbidity reductions and health care cost savings associated with lower risks of myocardial infarction, stroke, lung cancer and chronic obstructive pulmonary disease, were not considered. The reduction in all causes mortality risk consequential to quitting was incorporated into the model in order to accurately estimate the macular degeneration-related QALY gain associated with smoking cessation, but gains in life expectancy were not estimated. Our model predicted that smoking cessation was cost-effective even when only its impact on macular degeneration and mortality were considered. This finding was robust to all plausible variations in the model parameter estimates. Even assuming the slowest rate of decline in the risk of age-related macular degeneration after quitting, the incremental cost per QALY gained in 1,000 randomly selected smokers who quit was only $391.
Many effective interventions are available to encourage and assist smokers to quit. These include clinical treatments and services, such as counseling and pharmacotherapies, population-based interventions, such as mass-media anti-smoking advertising and telephone support (quit lines), and policies, such as increasing the price of tobacco products or smoking bans and restrictions. We based our analysis on an estimated cost per quitter for the comprehensive Massachusetts Tobacco Control Program, which comprised treatment services, a mass media campaign, a tobacco surcharge and other local policies. A wide range of costs per quitter have been reported for smoking cessation interventions, reflecting differences in the efficiency of interventions as well as differences in evaluation methodology. A recent review standardized evaluations of clinical interventions, by adjusting cost-effectiveness ratios to reflect a societal perspective and comply with guidelines for economic evaluation. Of the treatments considered, nicotine replacement therapy plus counseling, compared with counseling alone, had the highest incremental cost per quitter. The average adjusted cost per quitter in 4 studies was $9,100 in 2002 U.S. dollars. Much lower cost-effectiveness ratios have been reported for population-based interventions and policies. For example, adjusted costs per quitter of $298 – $1,593 (1997 U.S. dollars) for mass media education campaigns to promote smoking cessation were calculated by the Task Force on Community Preventive Services, smoke-free workplace policies were found to cost $799 per quitter (2002 U.S. dollars), and the American Cancer Society's telephone counseling service cost $1,300 per quitter (2000 U.S. dollars). All these cost-effectiveness ratios are considerably lower than the threshold cost we calculated of $77,000 per quitter, above which the incremental cost per QALY associated with smoking cessation exceeds $50,000. This indicates that our finding that smoking cessation is cost-effective in terms of its impact on macular degeneration alone is also robust to plausible variation in the cost per quitter, and can be generalized to most, if not all, tobacco control strategies.
In a previous paper, we assessed the cost-effectiveness of ranibizumab, a new therapy for the most common type of age-related macular degeneration. Ranibizumab is the first treatment for age-related macular degeneration that improves visual acuity and its efficacy has been described as miraculous. Over time horizons of 2 to 10 years we found that ranibizumab had incremental costs per QALY that would support description of the treatment as "cost-effective". Health care funding bodies have also concluded that ranibizumab's cost-effectiveness is acceptable. It has been recommended by NICE in the United Kingdom, and subsidized by the Australian government under its Pharmaceutical Benefits Scheme. In this paper, we assessed the cost-effectiveness of smoking cessation as a strategy to prevent macular degeneration over a different time period from the ranibizumab analysis – the remaining lifetime of a quitter, censored at age 85 – because the benefits of quitting accrue gradually over a long time period. We found that smoking cessation was unequivocally cost-effective in terms of age-related macular degeneration outcomes. Our model predicted gains in QALYs, and savings in the cost of macular degeneration treatment and the cost of care for people with impaired vision. Our findings have two potential practical applications. First, they will hopefully prompt ophthalmologists, who prescribe ranibizumab, to encourage patients to quit smoking in the interests of their sight. Second, our analysis will provide tobacco control advocates seeking government funding for anti-smoking programs with evidence that such programs are as justifiable on cost-effectiveness grounds as the newly available treatment for macular degeneration.
This analysis strongly supports the implementation of smoking cessation interventions to prevent age-related macular degeneration, because of their unequivocal cost-effectiveness.
We thank Dr Jamie La Nauze, MBBS, FRANZCO, for review of the manuscript and advice about the management of age-related macular degeneration.
This project was supported by a grant from the Cancer Council Victoria, through funding from the Victorian Health Promotion Foundation. The funding body had no role in the design and conduct of the study, in the collection, analysis and interpretation of the data, or in the preparation, review or approval of the manuscript.
- Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP: Smoking and age-related macular degeneration: a review of association. Eye 2005, 19: 935–944. 10.1038/sj.eye.6701978PubMedView ArticleGoogle Scholar
- Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, Hofman A, Jensen S, Wang JJ, de Jong PT: Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology 2001, 108: 697–704. 10.1016/S0161-6420(00)00580-7PubMedView ArticleGoogle Scholar
- Parrott S, Godfrey C: Economics of smoking cessation. BMJ 2004, 328: 947–949. 10.1136/bmj.328.7445.947PubMed CentralPubMedView ArticleGoogle Scholar
- Hurley SF, Matthews JP: The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking. Cost Eff Resourc Alloc 2007, 5: 2. 10.1186/1478-7547-5-2View ArticleGoogle Scholar
- Hurley SF, Matthews JP: Cost-effectiveness of the Australian National Tobacco Campaign. Tob Control 2008.Google Scholar
- Biener L, Harris JE, Hamilton W: Impact of the Massachusetts tobacco control programme: population based trend analysis. BMJ 2000, 321: 351–354. 10.1136/bmj.321.7257.351PubMed CentralPubMedView ArticleGoogle Scholar
- Hurley SF, Matthews JP, Guymer RH: Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc 2008, 6: 12. [http://www.resource-allocation.com/content/6/1/12] 10.1186/1478-7547-6-12PubMed CentralPubMedView ArticleGoogle Scholar
- TreeAge Pro 2006 User's Manual. Williamstown, MA: TreeAge Software Inc; 2006.Google Scholar
- Hussain B, Saleh GM, Sivaprasad S, Hammond CJ: Changing from Snellen to LogMAR: debate or delay? Clin Experiment Ophthalmol 2006, 34: 6–8. 10.1111/j.1442-9071.2006.01135.xPubMedView ArticleGoogle Scholar
- Smoking Status by Age, Sex, and Race/Ethnicity: United States, 1997–2005. National Health Interview Survey (NHISS05) National Center for Health Statistics. Centers for Disease Control 2007. Accessed: 1–10–2008 [http://www.cdc.gov/nchs/data/series/sr_10/sr10_228.pdf]
- Gold MR, Siegel JE, Russell LB, Weinstein MC, eds: Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.Google Scholar
- Klein R, Klein BE, Jensen SC, Meuer SM: The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997, 104: 7–21.PubMedView ArticleGoogle Scholar
- Tomany SC, Wang JJ, van Leeuwen R, Klein R, Mitchell P, Vingerling JR, Klein BE, Smith W, de Jong PT: Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004, 111: 1280–1287. 10.1016/j.ophtha.2003.11.010PubMedView ArticleGoogle Scholar
- Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE: A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA 1996, 276: 1147–1151. 10.1001/jama.276.14.1147PubMedView ArticleGoogle Scholar
- Seddon JM, Willett WC, Speizer FE, Hankinson SE: A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 1996, 276: 1141–1146. 10.1001/jama.276.14.1141PubMedView ArticleGoogle Scholar
- Evans JR, Fletcher AE, Wormald RP: 28,000 Cases of age related macular degeneration causing visual loss in people aged 75 years and above in the United Kingdom may be attributable to smoking. Br J Ophthalmol 2005, 89: 550–553. 10.1136/bjo.2004.049726PubMed CentralPubMedView ArticleGoogle Scholar
- Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JR, Bradley M, Moore AT, Bird AC: Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 2006, 90: 75–80. 10.1136/bjo.2005.073643PubMed CentralPubMedView ArticleGoogle Scholar
- Vingerling JR, Hofman A, Grobbee DE, de Jong PT: Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol 1996, 114: 1193–1196.PubMedView ArticleGoogle Scholar
- Delcourt C, Diaz JL, Ponton-Sanchez A, Papoz L: Smoking and age-related macular degeneration. The POLA Study. Arch Ophthalmol 1998, 116: 1031–1035.PubMedView ArticleGoogle Scholar
- McCarty CA, Mukesh BN, Fu CL, Mitchell P, Wang JJ, Taylor HR: Risk factors for age-related maculopathy: the Visual Impairment Project. Arch Ophthalmol 2001, 119: 1455–1462.PubMedView ArticleGoogle Scholar
- Breslow NE, Day NE: IARC Sci Publ. Lyon: International Agency for Research on Cancer; 1987:1–406.Google Scholar
- Steinbrook R: The price of sight – ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006, 355: 1409–1412. 10.1056/NEJMp068185PubMedView ArticleGoogle Scholar
- Halpern MT, Schmier JK, Covert D, Venkataraman K: Resource utilization and costs of age-related macular degeneration. Health Care Financ Rev 2006, 27: 37–47.PubMed CentralPubMedGoogle Scholar
- U.S. Medical Care. Consumer Price Index U.S.Department of Labour. Bureau of Labour Statistics 2007. Accessed: 2–5-2007 [http://www.bls.gov/data/home.htm]
- Brown GC, Sharma S, Brown MM, Kistler J: Utility values and age-related macular degeneration. Arch Ophthalmol 2000, 118: 47–51.PubMedView ArticleGoogle Scholar
- Miniño AM, Heron M, Murphy SL, Kochanek KD: Natl Vital Stat Rep. 2007,55(19):1–119.PubMedGoogle Scholar
- Taylor DH, Hasselbad V, Henley J, Thun MJ, Sloan FA: Benefits of Smoking Cessation for Longevity. Am J Public Health 2002, 92: 990–996.PubMed CentralPubMedView ArticleGoogle Scholar
- Behrendt C: Visual acuity and its decrease in classic neovascular age-related macular degeneration. Ophthalmic Epidemiol 2004, 11: 359–367. 10.1080/09286580490515125PubMedView ArticleGoogle Scholar
- Population Estimates for the U.S., Regions, and States by Selected Age Groups and Sex: Annual Time series, July 1, 1990 to July 1, 1999 (includes revised April 1, 1990 population counts) US Census Bureau 2007. Accessed: 11–5-2007 [http://www.census.gov/popest/archives/1990s/ST-99–09.txt]
- Consumer Price Index – All Urban Consumers. U.S. City Average. All items U.S.Department of Labor. Bureau of Labor Statistics 2007. Accessed: 11–5-2007 [http://data.bls.gov/cgi-bin/surveymost]
- The health consequences of smoking: a report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.Google Scholar
- Clinical Practice Guideline. Treating Tobacco Use and Dependence. 2000.Google Scholar
- Hopkins DP, Briss PA, Ricard CJ, Husten CG, Carande-Kulis VG, Fielding JE, Alao MO, McKenna JW, Sharp DJ, Harris JR, et al.: Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke. Am J Prev Med 2001, 20: 16–66. 10.1016/S0749-3797(00)00297-XPubMedView ArticleGoogle Scholar
- Ranson K, Jha P, Chaloupka FJ, Nguyen S: The effectiveness and cost-effectiveness of price increases and other tobacco-control policies. In Nicotine Tob Res. Volume 4. Edited by: Jha P, Chaloupka F. Oxford: Oxford University Press, for the World Bank and WHO; 2002:311–319. 10.1080/14622200210141000Google Scholar
- Warner KE: Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence and implications for coverage. Pharmacoeconomics 1997, 11: 538–549.PubMedView ArticleGoogle Scholar
- Ronckers ET, Groot W, Ament AJ: Systematic review of economic evaluations of smoking cessation: standardizing the cost-effectiveness. Med Decis Making 2005, 25: 437–448. 10.1177/0272989X05278431PubMedView ArticleGoogle Scholar
- Ong MK, Glantz SA: Free nicotine replacement therapy programs vs implementing smoke-free workplaces: a cost-effectiveness comparison. Am J Public Health 2005, 95: 969–975. 10.2105/AJPH.2004.040667PubMed CentralPubMedView ArticleGoogle Scholar
- Stone EM: A very effective treatment for neovascular macular degeneration. N Engl J Med 2006, 355: 1493–1495. 10.1056/NEJMe068191PubMedView ArticleGoogle Scholar
- Final appraisal determination. Ranibizumab and pegaptanib for age-related macular degeneration National Institute for Health and Clinical Excellence 2008. Accessed: 24–4-2008 [http://www.nice.org.uk/guidance/index.jsp?action=download&o=40254]
- Australian Government Department of Health and Ageing: New PBS listings for the treatment of Age-related Macular Degeneration. PBS for health professionals 2007. Accessed: 4–8-2008 [http://www.pbs.gov.au/html/healthpro/news/article?id=NEWS-2007–06–06-Listing_of_Lucentis.xml]Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.